Identification of Clostridium difficile Ribotype 027 for the First Time in Mainland China

was 1.60 (95% confidence interval [CI], 1.02-2.51), P = .04. 2. Of those subjects who received a PPI and vancomycin alone, the relapse rate was 28.0% (7/25), compared to 10.3% (8/78) in those who received vancomycin alone and no PPI. The unadjusted OR was 3.40 (95% CI, 1.0910.63), P = .05. 3. Of those who received any treatment (metronidazole or vancomycin or both) and a PPI, the relapse rate was 33.8% (68/201), compared to 21.7% (123/568) for those who did not receive a PPI. The unadjusted OR was 1.85 (95% CI, 1.30-2.64), P<.01. 4. Of those patients who received both metronidazole and vancomycin as well as a PPI, the relapse rate was 42.9% (21/49), compared to 26.2% (37/141) for those who received both agents but not a PPI. The unadjusted OR was 2.11 (95% CI, 1.07-4.16), P = .03.

[1]  H. Daniell.  Increased Clostridium difficile Recurrences following Combined Proton Pump Inhibitor–Metronidazole Therapy , 2014, Infection Control &#x0026; Hospital Epidemiology.

[2]  Hongyan Du,et al.  Electronic Health Record–Based Detection of Risk Factors for Clostridium difficile Infection Relapse , 2013, Infection Control &#x0026; Hospital Epidemiology.

[3]  Haijian Zhou,et al.  Multilocus sequence typing (MLST) analysis of 104 Clostridium difficile strains isolated from China , 2012, Epidemiology and Infection.

[4]  Jieun Kim,et al.  Epidemiology and Clinical Characteristics of Clostridium difficile Infection in a Korean Tertiary Hospital , 2011, Journal of Korean medical science.

[5]  C. Tae,et al.  The First Case of Antibiotic-associated Colitis by Clostridium difficile PCR Ribotype 027 in Korea , 2009, Journal of Korean medical science.

[6]  B. Coignard,et al.  First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. , 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  P. Mastrantonio,et al.  Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. , 2004, Journal of medical microbiology.

[8]  P. Mastrantonio,et al.  Molecular Analysis of the Pathogenicity Locus and Polymorphism in the Putative Negative Regulator of Toxin Production (TcdC) among Clostridium difficile Clinical Isolates , 2002, Journal of Clinical Microbiology.

[9]  M. Rupnik,et al.  Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. , 2000, FEMS microbiology letters.

[10]  Kunitomo Watanabe,et al.  Identification of Toxin A-Negative, Toxin B-Positive Clostridium difficile by PCR , 1998, Journal of Clinical Microbiology.

[11]  C. Ou,et al.  Identification of toxigenic Clostridium difficile by the polymerase chain reaction , 1991, Journal of clinical microbiology.

[12]  Beiqin Yu,et al.  Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital. , 2013, International journal of antimicrobial agents.

[13]  These authors contributed equally to this work. , 2007 .